Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia.

Sci Rep

Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Published: June 2020

Helicobacter pylori (H. pylori) infection is on the rise as a cause of immune thrombocytopenia (ITP). It has been suggested that platelet recovery can be achieved following successful microbial eradication, although, the exact pathophysiology has yet to be fully elucidated. This study evaluated the long-term effects of H. pylori eradication monotherapy on platelet count recovery in patients with ITP. H. pylori eradication was analysed in 61 ITP patients. Patients who maintained a complete response (CR) for more than six months were classified as sustained responders (SR). The prevalence of H. pylori infection was 54.3% (75/138), and the success rate of eradication with first-line therapy was 71.4% (35/49). Patients who had achieved a CR at 2 months maintained a higher platelet count thereafter. At 1 year following eradication, platelet counts had increased 2.78 times in the eradicated group, 1.36 times in the sustained infection group, and 1.33 times in the no infection group compared with the baseline (P = 0.016).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287131PMC
http://dx.doi.org/10.1038/s41598-020-66460-5DOI Listing

Publication Analysis

Top Keywords

pylori eradication
12
platelet count
12
helicobacter pylori
8
eradication platelet
8
count recovery
8
immune thrombocytopenia
8
pylori infection
8
infection group
8
eradication
6
platelet
5

Similar Publications

Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes.

Sci Rep

January 2025

Department of Gastroenterology, Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, 68 Gehu Middle Road, Wujing District, Changzhou, 213000, Jiangsu, China.

Patients with diabetes have a high risk of failure of H. pylori eradication therapy. The present study aims to evaluate the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy for the treatment of H.

View Article and Find Full Text PDF

Understanding and Preventing Advanced Gastric Cancer in Young Hispanic Patients.

Cancer Epidemiol Biomarkers Prev

January 2025

Keck School of Medicine, University of Southern California, Los Angeles, California.

The risk of gastric cancer among immigrants from countries where Helicobacter pylori is endemic greatly exceeds those born in the United States. Among patients in the Los Angeles safety-net health system, the risk of advanced and fatal gastric cancer is higher in Hispanic versus non-Hispanic patients. There is an urgent need to define whether this reflects concomitant illnesses, such as metabolic disease, occupational exposures, or differential access to H.

View Article and Find Full Text PDF

Background: A dual therapy regimen containing amoxicillin is a common treatment option for the eradication of (). While substantial research supports the efficacy and safety of vonoprazan and amoxicillin (VA) dual therapy in the general population, there is still a lack of studies specifically focusing on its safety in elderly patients.

Aim: To evaluate efficacy and safety of VA dual therapy as first-line or rescue treatment for in elderly patients.

View Article and Find Full Text PDF

Experience of Metronidazole Triple Therapy After Clarithromycin Triple Therapy Failure for Eradication in Korea.

J Clin Med

December 2024

Department of Internal Medicine, Gyeongsang National University College of Medicine, Gyeongsang National University Hospital, Jinju 52727, Republic of Korea.

Bismuth quadruple therapy (BQT) is recommended as the best second-line regimen after failure of first-line clarithromycin triple therapy (CTT) for eradication. However, there are some limitations to this approach, including the lack of an appropriate sequel regimen after failure of BQT and complicated administration. Metronidazole triple therapy (MTT) is simple to administer, but it is not widely recommended.

View Article and Find Full Text PDF

Background/objectives: Since 2013, eradication therapy for gastritis (-ET) has been covered by the National Health Insurance of Japan. Recently, the risk of post-eradication gastric cancer (pE-GC) has increased. pE-GC includes cancers that develop immediately and several years after -ET.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!